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Summary
 
Background
 
No data on results of repeated transsphenoidal surgery
via the endoscopic technique for patients with persistent or recurrent
Cushing’s disease are available.
 
Design and patients
 
We retrospectively evaluated the remission
rates and complications of repeated transsphenoidal surgery via the
endoscopic technique in 14 patients with persistent (
 
N
 
 = 6) or
recurrent (
 
N
 
 = 8) Cushing’s disease treated in our centre between
1999 and 2007.
 
Main outcomes
 
Remission was defined as the disappearance
of symptoms of hypercortisolism with basal plasma cortisol
level 
 
≤
 
 50 nmol/l 24–48 h after glucocorticoid withdrawal and/or
suppression of plasma cortisol level 
 
≤
 
 50 nmol/l after 1 mg dexam-
ethasone overnight within the first 3 months after transsphenoidal
surgery.
 
Results
 
With repeated endoscopic transsphenoidal surgery a
remission rate of 10/14 (71%) was achieved. No patient had a relapse
during a median follow-up of 24 months. Cerebrospinal fluid leakage
was the most frequent complication (6 patients) and 11 patients
required hormonal substitution after surgery. The success of
repeated transsphenoidal surgery could not be predicted by
visualization of an adenoma on MRI before first or second surgery,
histopathological confirmation of an ACTH secreting adenoma after
first or second surgery, treatment with cortisol lowering agents
before first or second surgery, the operation technique used during
the first surgery, persistent 
 
vs.
 
 recurrent disease after the first surgery,
age, gender and interval between the two surgeries.
 
Conclusion
 
Repeated transsphenoidal surgery via the endoscopic
technique is a good treatment option for selected patients with
recurrent or persistent Cushing’s disease following primary pituitary
surgery.
(Received 16 April 2008; returned for revision 3 May 2008; finally 
 
revised 13 June 2008; accepted 23 June 2008)
 
Introduction
 
Cushing’s disease (CD) is a potentially life threatening condition that
requires aggressive treatment.
 
1,2
 
 At present transsphenoidal pituitary
surgery (TS) is the primary treatment of choice. Remission rates vary
from 50% to 90%. However, CD persists in the remaining patients,
and 5–25% of the patients who are initially in remission develop a
recurrence.
 
3–8
 
 Treatment options for persistent or recurrent CD
include radiation therapy, bilateral adrenalectomy, medical therapy
and repeated TS. Thus far, no consensus exists on which therapy is
preferable.
 
5,9,10
 
Pituitary radiotherapy has been used to treat persistent or recurrent
CD for several decades. Remission rates after conventional fractionated
radiation therapy range from 56% to 84%.
 
5,9
 
 However, its usefulness
is limited by the delay between therapy and disease control and the
50–100% incidence of hypopituitarism several years after treatment.
Additional complications include radiation necrosis, cerebral
vasculopathy, damage to surrounding structures and the develop-
ment of radiation-induced neoplasms. Stereotactic radiosurgery,
which was introduced more recently, may lead to faster normalization
of hormone levels with a lower complication risk than conventional
radiotherapy, but long-term follow-up is needed to determine its real
value.
 
5,9,11,12
 
Bilateral adrenalectomy has a very high success rate of reversing
hypercortisolism, ranging from 88% to 100%. Traditionally, open
procedures of adrenalectomy were associated with considerable
morbidity and mortality.
 
13,14
 
 Nowadays the minimally invasive
laparoscopic approach is preferred, which has reduced perioperative
morbidity significantly.
 
9,15
 
 However, adrenalectomized patients
require lifelong glucocorticoid and mineralocorticoid replacement.
The major concern is the development of Nelson’s syndrome in
15–46% of the patients.
 
5,16,17
 
Medical therapy in CD mostly serves an adjunctive role after
unsuccessful TS. At present only steroidogenesis inhibitors have been
proven effective. Furthermore, discontinuation of medical treatment
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will invariably result in recurrence of CD and all available medicaments
have significant side-effects.
 
18
 
Repeated TS may be a good treatment option for persistent or
recurrent CD. It has the potential to instantly cure CD, while adrenal
and pituitary function may remain intact. However, few investigators
have addressed the results of repeated TS and the reported risk of
hypopituitarism and other complications is higher than after the first
TS.
 
19–26
 
 Furthermore all previous studies operated upon patients via
the conventional microscopic technique of TS. Cappabianca 
 
et al
 
.
have suggested that the endoscopic technique of TS might be
considered the procedure of choice in recurrent or residual pituitary
adenomas, as the wider and direct visual control of the surgical field
provides an advantage if the anatomy has been distorted by previous
surgery.
 
27
 
 No results on repeated TS via the endoscopic technique
in CD have been published till now.
 
27,28
 
In order to gain insight into the role of repeated TS as a treatment
option for persistent or recurrent CD, we evaluated the remission
rates and complications of repeated TS in 14 patients, treated in our
hospital between 1999 and 2007. All patients were operated via the
endoscopic technique.
 
Patients and methods
 
Patients
 
Between 1999 and 2007, 68 endoscopic TS were carried out for CD
in our hospital. Fourteen of these operations were repeated TS, for
persistent CD in six patients and recurrent CD in eight patients. The
medical records of these patients were retrospectively reviewed.
There were five males and nine females and age at time of the second
surgery was 37·2 ± 10·3 years (Table 1).
Between 1999 and 2007 a total of 24 patients were treated for
persistent or recurrent CD. Besides the 14 patients who underwent
endoscopic repeated TS, 5 patients underwent conventional
pituitary radiotherapy, 4 patients underwent stereotactic
radiosurgery and 1 patient underwent a bilateral adrenalectomy.
A multidisciplinary team of neurosurgeons, endocrinologists and a
radiotherapist decided which therapy for persistent or recurrent
CD was the optimal therapy for each individual patient, taking
into account the invasiveness of the adenoma, findings at previous
surgery, the physical condition of the patient and the patient’s
preference.
 
Diagnostic evaluation before the first and second TS
 
The initial diagnosis of hypercortisolism was based on clinical
symptoms and biochemical tests, including 24-h urinary free cortisol
measurements, assessment of the plasma cortisol and ACTH circadian
rhythm and an overnight low dose dexamethasone suppression
test (1 mg at 11 pm).
 
29
 
 A CRH-test (100 
 
μ
 
g human CRH i.v.)
 
30
 
 and
a high-dose dexamethasone suppression test
 
31
 
 was performed in
most patients. In addition pituitary imaging by contrast enhanced
magnetic resonance imaging (MRI) was performed in all patients,
except in one patient where contrast enhanced computed tomography
Table 1. Clinical characteristics per patient: first and second transsphenoidal pituitary surgery (1999–2007)
Patient number, 
Gender, Age (years)
First surgery
1st–2nd 
surgery 
(months)
Second surgery
MRI Technique Histology Result CLA MRI Year Technique Histology
Cortisol (nmol/l) 
ResultBasal After dex
1, f, 36 < 10* TE + R 131 – < 10 1999 Endo TS + 0·50 0·02 R
2, f, 45 – Endo TS – F 2 M – 2001 Endo TS – 0·05 0·02 R
3, f, 36 – Endo TS – F 3 – – 2002 Endo TS – 0·55 0·21 F
4, m, 30 – Endo TS – R 11 M < 10 2002 Endo TS – 0·02 0·05 R
5, m, 41 < 10 TS + R 98 K < 10, in 2005 Endo TS NT 0·38 – F
6, f, 30 < 10 Endo TS – F 5 K < 10 2005 Endo TS + 0·57 0·25 F
7, m, 46 < 10 TS + F 185 K < 10 2005 Endo TS + 0·05 0·07 R
8, f, 22 < 10 Endo TS – F 38 K < 10 2006 Endo TS – 0·59 0·50 F
9, m, 27 < 10 Endo TS + R 53 – 22, in 2006 Endo TS + 0·15 0·04 R
10, f, 40 35 Endo TS – R 41 – < 10 2006 Endo TS + 0·02 0·03 R
11, m, 56 < 10 TS + R 124 – < 10 2006 Endo TS + 0·21 0·02 R
12, f, 27 – Endo TS – F 2 K < 10 2006 Endo TS – 0·01 – R
13, f, 54 – Endo TS – R 32 – – 2006 Endo TS – 0·02 – R
14, f, 31 < 10 TS – R 104 – < 10 2007 Endo TS + 0·01 – R
Age, age at second surgery; f, female; m, male; MRI, magnetic resonance imaging results given as maximal diameter of the visualized adenoma in mm; MRI*, 
computed tomography scan was made instead of an MRI scan; MRI – , no adenoma identified; MRI in, invasion in cavernous sinus or other parasellar structures; 
TE, transethmoidal pituitary surgery; TS, microscopic transsphenoidal pituitary surgery; Endo TS, endoscopic transsphenoidal pituitary surgery; Histology 
+, evidence of ACTH producing adenoma on histological examination; Histology –, no evidence of ACTH producing adenoma on histological examination; 
Histology NT, no tissue obtained during surgery; CLA, preoperative therapy with cortisol lowering agents; M, metyrapone; K, ketoconazole; Cortisol basal, fasting 
plasma cortisol level at 0800 h on seventh day after surgery; dex, plasma cortisol level at 0800 h after 1 mg dexamethasone overnight; R, remission; F, failure.
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(CT) scanning was used, to search for a pituitary adenoma. Eight
patients underwent bilateral inferior petrosal sinus sampling with i.v.
stimulation with 100 
 
μ
 
g human CRH, which confirmed the pituitary
origin of hypercortisolism in all eight patients.
 
32
 
To document the persistence of hypercortisolism after TS or
relapse of hypercortisolism in patients who were in remission for
some time after TS, 24-h urinary free cortisol was measured, an
overnight 1 mg dexamethasone suppression test was performed,
and midnight plasma cortisol was assessed. A new MRI scan was
performed before the second TS in all patients.
 
Surgical procedures
 
All repeated pituitary operations in this series were performed via
an endoscopic binostril endonasal transsphenoidal technique. This
technique was introduced in our hospital in 1994, and first used for
CD in 1997. From 1998 onward practically all TS were performed
endoscopically. The surgeries were exclusively performed by two
neurosurgeons. The technique is very similar to the technique
that Jho 
 
et al
 
. and Cappabianca 
 
et al
 
. have described previously.
 
33–36
 
However, a binostril, transsphenoidal, endoscopic approach to
the sella turcica during which the endoscope is handheld was
used.
For endoscopic transnasal TS 0
 
°
 
 and 30
 
°
 
 rigid endoscopes with a
lens diameter of 4 mm with a separate shaft were used, which allow
easy and comfortable holding, while offering a suction-irrigation-
system for cleaning the lens (Karl Storz GmbH, Tuttlingen, Germany).
The instruments used are principally the same as with the
microsurgical technique. The technique of repeated surgery is in no
way different from primary surgery. In two recent cases electromagnetic
neuronavigation was used for orientation and localization of a very
small tumour.
In patients with recurrent CD a selective adenomectomy was
performed if MRI identified the tumour. In case of negative MRI
investigations a hemihypophysectomy was performed based on
intra-operative findings. In patients with persistent CD after first TS,
a total hypophysectomy was performed during repeated TS.
Although this term suggests complete removal of all contents of the
sella, it is never the intention to remove all pituitary tissue. Total
hypophysectomy indicates the surgical exploration of the complete
contents of the sella and removal of all anterior pituitary tissue that
might harbour adenoma tissue. As soon as this goal seems to be
achieved further surgery is discontinued and thus pituitary tissue
may be left in place.
 
Perioperative treatment
 
Cortisol lowering agents, metyrapone and/or ketoconazole, were
given for a period of 4 months preoperatively in 9 patients before
the first TS and in 7 patients before the second TS.
Administration of glucocorticoids i.v. (prednisolone, 25 mg every
8 h) was started one hour before surgery. After 2 days glucocorticoids
were given orally and the dose was tapered rapidly. There was an
interval of at least 48 h between the last dose of glucocorticoids and
the first postoperative measurement of fasting plasma cortisol on the
seventh day postoperatively.
 
Postoperative evaluation after first and second TS
 
On the seventh day postoperatively early biochemical evaluation
was carried out, consisting of measurement of fasting (8 am) plasma
cortisol. If it was lower than 200 nmol/l substitution therapy with
hydrocortisone, 30 mg a day, or cortisone acetate, 37·5 mg daily, was
prescribed. Patients were re-evaluated every 2–4 weeks during the
first 3 months after surgery and then at 2–3 months intervals during
the first year. Thereafter they were evaluated at least once a year.
The fasting plasma cortisol concentration was measured at each
visit. In addition an overnight 1 mg dexamethasone suppression test
was carried out in 1 and 3 months postoperatively, and thereafter in
patients who were in remission once yearly or earlier in case of clinical
suspicion of relapse. If a patient received glucocorticoid substitution
postoperatively, the dose was reduced gradually and stopped, if
possible, between 3 and 12 months after surgery. Thereafter the
integrity of the hypothalamic–pituitary–adrenal axis was assessed by
an insulin-hypoglycaemia test.
 
37
 
 The thyrotrophic, gonadotrophic
and somatotrophic axis were checked regularly.
 
Criteria for remission and relapse
 
Remission was defined as disappearance of clinical symptoms of
hypercortisolism with basal plasma cortisol level 
 
≤
 
 50 nmol/l after
glucocorticoid withdrawal for 24–48 h and/or suppression of plasma
cortisol level 
 
≤
 
 50 nmol/l after overnight 1 mg dexamethasone
within the first 3 months after surgery.
 
6,7,10
 
 Relapse was defined as
development of clinical symptoms of hypercortisolism and
inadequate suppression of plasma cortisol level after an overnight
1 mg dexamethasone suppression test in patients who were in
remission after the first surgery according to the previously
mentioned criteria.
 
Statistics
 
Statistical analyses were performed using Pearson’s 
 
χ
 
2
 
-tests (P) and
Wilcoxon’s two sample tests (P*). Statistical significance was defined
as 
 
P
 
 < 0·05 (two tailed).
 
Results
 
Remission rates after repeated TS (Fig. 1)
 
The individual clinical data of the 14 patients are shown in Tables 1
and 2. The mean interval between the first and the second TS was
59 months (median 39, range 2–185).
After repeated TS remission was achieved in 10 patients. Never-
theless, patients 1 and 9 received additional therapy. Patient 1 was
concerned that hypercortisolism would recur and asked for
additional radiotherapy. Patient 9 was the only patient with an
invasive macro-adenoma that could not entirely be removed during
the second surgery. Therefore the patient received additional gamma
knife surgery although he was clinically and biochemically in
remission.
None of the patients who were in remission after the second TS
had a relapse during follow-up of mean 34 months (median 24,
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range 4–97). At last follow-up plasma cortisol was not suppressed
to 
 
≤
 
 50 nmol/l after 1 mg dexamethasone overnight in patients 1, 2,
7 and 10 (Table 2), but they had no clinical symptoms of hyper-
cortisolism and 24-h urinary free cortisol excretion was not elevated.
Four patients had persistent CD after the second TS. Patient 3
underwent a bilateral adrenalectomy and patients 5, 6 and 8 received
conventional radiotherapy.
There were no statistically significant differences between the
patients who underwent successful or unsuccessful repeated TS with
respect to the following parameters: visualization of an adenoma on
MRI before first or second TS, histopathological confirmation of an
ACTH secreting adenoma after first or second TS, treatment with
cortisol lowering agents before first or second TS, the operation
technique used during the first TS, persistent 
 
vs.
 
 recurrent disease
after the first TS, age, gender and interval between the two TS.
 
Complications of repeated TS
 
Six of the 14 patients had mild transient diabetes insipidus. Six
patients had cerebrospinal fluid (CSF) leakage, 4 intra-operatively
Fig. 1 Results of repeated transsphenoidal pituitary surgery via the endoscopic technique in patients with persistent of recurrent Cushing’s disease (1999–
2007). ADX, bilateral adrenalectomy.
Table 2. Substitution therapy and follow-up after second pituitary surgery (1999–2007)
Patient 
number
Substitution 
after first TS*
Substitution 
after second TS**
Result second
surgery
Additional 
therapy
Cortisol at last 
follow-up (nmol/l)
Follow-up
(months)Basal After dex
1 – – R CR (45 Gy) 0·46 0·08 94
2. – T, GH R – 0·57 0·06 83
3. – T F ADX – – 68
4. – A, GH, G R – 0·15 0·03 61
5. – – F CR (50 Gy), K – – 30
6. T T F CR (50 Gy) – – 28
7. – T, G R – 0·13 0·09 30
8. – T F CR (45 Gy), K – – 15
9. – A R RS 0·10 < 0·02 17
10. – T R – 0·18 0·08 15
11. T T, GH R – 0·26 < 0·02 15
12. – – R – 0·40 < 0·02 13
13. – G R – 0·06 < 0·02 13
14. G,T,GH,E G,T,GH,E R – 0·04 < 0·02 3
*At last evaluation before relapse was diagnosed or in case of persistent Cushing’s disease immidiately before second TS; **, At last follow-up; A, androgens; 
D, desmopressin; E, estrogens; G, glucocorticoids; GH, growth hormone; T, levothyroxine; CR, conventional radiotherapy; RS, radiosurgery; ADX, bilateral 
adrenalectomy; K, ketoconazole; Cortisol at last follow-up, fasting plasma cortisol level at 0800 h and plasma cortisol level at 0800 h after 1 mg dexamethasone 
overnight, measured in January 2008 in patients who are clinically in remission after 2nd surgery.
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(closed with a fat graft) and 2 postoperatively. All six patients with
CSF leakage were treated successfully with an external lumbar drain.
Two patients required a reoperation to close the leak. More serious
complications occurred in two patients. Patient 5 had blood loss
from the right cavernous sinus during second TS. Damage of the
internal carotid artery was excluded via an angiogram. Surgery was
terminated before any tissue was removed and a tampon was placed
that was removed via reexploration 1 week later. A few hours after
the reexploration the patient developed a hemiparesis, due to occlusion
of the left internal carotid artery just above the bifurcation. This was
very unlikely a direct complication of the TS because the site of
occlusion of the internal carotid artery was lower than the operation
area. Although the patient improved significantly during the
revalidation process, permanent disabilities remain. Patient 11 had
postoperative bleeding from the sphenopalatine artery. Reexploration
was required with successful coagulation of the artery. The patient
recovered within a few days without other complications.
Only three patients required hormonal substitution after the first
TS. After the second TS 11 patients required long-term hormonal
substitution (Table 2). Of all patients, 8 required levothyroxine, 4
glucocorticoids, 4 GH and 2 androgens and one oestrogens after
repeated TS.
 
Discussion
 
The present study is the first study to report on the outcome of
repeated TS via the endoscopic technique in patients with persistent
or recurrent CD. In 1994 the endoscopic technique for TS was
introduced in our hospital. Because of the minimal invasiveness, the
excellent view of the surgical field and wider working angle, practically
all TS were done endoscopically from 1998 onward. Before the
introduction of the endoscopic technique we regarded repeated TS
as a technically difficult procedure. Therefore, most patients with
persistent and recurrent CD treated in our centre before 1999
underwent bilateral adrenalectomy or radiotherapy, and only four
patients underwent repeated TS. Only one of these four patients was
cured. After the introduction of the endoscopic technique repeated
TS became more feasible. The wider view of the endoscopic
technique provides an advantage, during repeated TS, as the
anatomy is altered due to the previous operation.
 
27
 
 A substantially
higher remission rate of 71% was achieved in the 14 patients
operated on endoscopically and there was no relapse during follow-
up of median 24 months.
The remission rate of 71% achieved in this study compares
favourably with the remission rates previously reported after
repeated TS via the conventional microscopic technique, which vary
between 37% and 73%, with a 0–25% relapse rate
 
19–24
 
 (Table 3).
When comparing the reported remission rates, it is important to
note that the studies were carried out in different patient groups.
Three studies included patients with both persistent and recurrent
CD,
 
19–21
 
 whereas other studies reported on patients with either
persistent
 
22,23
 
 or recurrent
 
24
 
 CD. Criteria for remission also differed.
In three studies immediate repeated TS was performed in case of
persistent CD.
 
21–23
 
 However, this strategy ignores the fact that some
patients who do not have a low early postoperative basal plasma
cortisol level do achieve remission, so by using this strategy some
patients will unnecessarily undergo immediate repeated TS.
 
8
 
 Overall,
the remission rates reported after second TS in persistent or recurrent
CD seem to be slightly lower than the remission rates reported after
first TS which vary from 50% to 90%, but are mostly 70–85%.
 
3–9
 
Nevertheless, the majority of the patients with persistent or recurrent
CD can still instantly be cured by repeated TS, and the remission
rate we achieved via the endoscopic technique seems to be at least
as good as the remission rate achieved by repeated TS via the
conventional microscopic technique.
In this study 57% of the patients had a perioperative complication
of the repeated TS. Although most complications in our series were
mild and transient more serious complications occurred in two
patients: one patient had a cerebrovascular accident postoperatively
and another patient had postoperative bleeding from the sphenopal-
atine artery. The latter complication is not a rare complication of
microscopic TS, occurring in 3·4% of all cases. Vascular complications
of endoscopic TS and microscopic TS are identical.
 
38
 
 We previously
reported a complication rate of 29% in our study on results of
primary endoscopic TS in patients with CD,
 
3
 
 which is similar to the
complication rates reported in studies of primary microscopic TS in
patients with CD. The studies on repeated TS in patients with
persistent or recurrent CD report complication rates varying
between 0% and 91%.
 
19–24
 
 Although complication rates are influenced
substantially by differences in definitions, the complication rate
of repeated TS seems to be higher than the complication rate of
primary TS.
Especially CSF leakage has been reported to occur more frequently
during repeated TS than during the first TS, probably because of
postoperative changes such as scar tissue but also as a result of a more
aggressive surgical procedure in a usually small sella with a concave
Table 3. Overview of previously published results of repeated TS in patients with persistent or recurrent CD
Population Criteria remission Remission (%) Relapse (%)
Friedman et al. (1989) 33 persistent + recurrent Morning C < 6 μg/dl and UFC < 90 μg/day 73 13
Ram et al. (1994) 17 persistent* Morning C < 5 μg/dl and UFC < 90 μg/day 71 25
Knappe et al. (1996) 10 persistent*/17 recurrent Not defined 71/56 24/22
Benveniste et al. (2005) 44 persistent + recurrent Not defined 57 25
Locatteli et al. (2005) 12 persistent* Clinical symptoms of hypocortisolism and morning C ≤ 2 μg/dl 67 0
Hofman et al. (2006) 16 recurrent C < 2 μg/dl after 2 mg dexamethasone and morning C 10–21 μg/dl 37 0
TS, transsphenoidal pituitary surgery; CD, Cushing’s disease; *, immediate reoperation; C, plasma cortisol; UFC, urinary free cortisol excretion.
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diaphragm.
 
22,28,39
 
 CSF leakage occurred in 43% of the patients in this
study, intra-operatively in four patients and postoperatively in two
patients. Previously, we reported a CSF leakage rate of 8·5% in
primary endoscopic TS in patients with CD operated on by the
same neurosurgeons that operated the patients in this study.
 
3
 
 When
comparing rates of CSF leakage it is important to note that most
studies only report on the rates of postoperative CSF leakage. The
rate of postoperative CSF leakage is lower (1–4% during first TS)
than the rate of intra-operative CSF leakage (9–25% during first
TS).
 
39,40
 
 Because intra-operative CSF leakage, which is usually not
regarded as a complication, also occurs frequently during the first
TS and the risk of meningitis is minimal if patients are given a lumbar
drain,
 
41
 
 we believe that the higher chance of CSF-leakage during
repeated TS should not be a reason to refrain from repeated TS.
The chance of hypopituitarism after repeated TS is higher than
after the first TS. Reported percentages of hormonal deficiencies in
patients with CD after the first TS vary from 2% to 48%, but are
mostly around 20%. Ram 
 
et al
 
.
 
23
 
 and Friedman 
 
et al
 
.
 
20
 
 reported rates
of hormonal deficiencies after repeated TS in 41% and 50% of the
patients. Locatelli 
 
et al
 
. found an extremely high rate of hormonal
deficiencies (100%), but all patients underwent a total hypophy-
sectomy.
 
22
 
 Hofmann 
 
et al
 
.
 
24
 
 and Knappe 
 
et al
 
.
 
21
 
 report on new
hormonal deficiencies in 0% and 8%. In the present series the
percentage of patients with hormonal deficiencies was 78% after the
second TS, with six patients having only one hormonal deficiency.
The rate of hormonal deficiencies was 48% in our earlier study on
results of first endoscopic TS in patients with CD.
 
3
 
 The higher rates
of hypopituitarism after repeated TS compared to after the first TS
can be expected because additional pituitary tissue is removed. Even
so, the risk of hypopituitarism after second TS seems to be lower than
reported rates of hypopituitarism several years after radiotherapy.
 
9,11
 
The success rate of repeated TS for persistent or recurrent CD
depends on the correct selection of patients. In our opinion TS is a
good treatment option if there is a reasonable chance that it will be
successful. CD can be controlled instantly with the possibility to
normalize cortisol circadian rhythm and keep the pituitary adrenal
axis intact. Radiotherapy, however, is a good option if an adenoma
is invasive.
Success rates of TS also critically depend on the skills and the
experience of the neurosurgeons.
 
42
 
 Repeated TS is an even more
difficult procedure than a first TS and repeated TS is infrequently
performed. Thus it is advised to concentrate repeated TS for CD in
a limited number of specialized centres.
In conclusion, repeated transsphenoidal pituitary surgery (TS) is
a good therapeutic option for selected patients with persistent or
recurrent Cushing’s disease (CD), with the potential to achieve
remission in the majority of patients. The remission rate of 71% we
achieved via the endoscopic technique of repeated TS compares
favourably with the remission rate of repeated TS via the conven-
tional microscopic technique previously described in the literature.
The excellent view of the surgical field during endoscopic TS
provides an advantage in case of altered anatomy due to previous
surgery. However, only a randomized trial can definitively assess
whether the endoscopic or the microscopic technique of TS is the
preferred technique for repeated surgery in patients with persistent
or recurrent CD.
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